We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+3.53%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.33%
AUM
$12B
AUM Growth
-$353M
Cap. Flow
-$617M
Cap. Flow %
-5.16%
Top 10 Hldgs %
12.46%
Holding
637
New
171
Increased
105
Reduced
150
Closed
191

Top Buys

Rank Stock Value
1
DAL icon
Delta Air Lines
DAL
+$140M
2
ABBV icon
AbbVie
ABBV
+$119M
3
KEY icon
KeyCorp
KEY
+$115M
4
FFIV icon
F5
FFIV
+$111M
5
WMT icon
Walmart Inc
WMT
+$110M

Top Sells

Rank Stock Value
1
ORCL icon
Oracle
ORCL
+$146M
2
SPGI icon
S&P Global
SPGI
+$142M
3
LLY icon
Eli Lilly
LLY
+$133M
4
LH icon
Labcorp
LH
+$131M
5
RHT
Red Hat Inc
RHT
+$121M

Sector Composition

Rank Sector Weight
1 Technology 17.86%
2 Healthcare 13.19%
3 Industrials 12.91%
4 Consumer Discretionary 10.27%
5 Financials 9.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLJE
426
CALL
DELISTED
RLJ Entertainment, Inc.
RLJE
$662K 0.01%
200,000
– –
TRTN
427
DELISTED
Triton International Limited
TRTN
$647K 0.01%
+19,338
New +$571K
LADR
428
Ladder Capital
LADR
$1.2B
$641K 0.01%
47,821
-996,182
-95% -$14.3M
NVCN
429
DELISTED
Neovasc Inc.
NVCN
$639K 0.01%
19
-2
-10% -$76.9K
ECPG icon
430
Encore Capital Group
ECPG
$1.99B
$628K 0.01%
+15,636
New +$561K
PZZA icon
431
Papa John's
PZZA
$979M
$625K 0.01%
+8,705
New +$688K
OBSV
432
DELISTED
ObsEva SA Ordinary Shares
OBSV
$574K ﹤0.01%
67,118
-2,034
-3% -$15.1K
ALBO
433
DELISTED
Albireo Pharma Inc
ALBO
$573K ﹤0.01%
+27,796
New +$570K
SYRE icon
434
Spyre Therapeutics
SYRE
$9.06B
$442K ﹤0.01%
4,593
-140
-3% -$19.4K
YEXT icon
435
Yext
YEXT
$574M
$433K ﹤0.01%
+32,495
New +$438K
LITE icon
436
Lumentum
LITE
$64.3B
$395K ﹤0.01%
+6,917
New +$371K
NTBL
437
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$371K ﹤0.01%
2,381
– –
TBCH
438
Turtle Beach Corp
TBCH
$269M
$309K ﹤0.01%
110,416
-3,346
-3% -$10.8K
ATXS
439
DELISTED
Astria Therapeutics
ATXS
$303K ﹤0.01%
3,580
-108
-3% -$8.99K
TCON
440
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$230K ﹤0.01%
480
-14
-3% -$8.54K
AIXC
441
AIxCrypto Holdings Inc
AIXC
$15.6M
$161K ﹤0.01%
2
-1
-33% -$95.8K
ENSV
442
DELISTED
Enservco Corp.
ENSV
$104K ﹤0.01%
22,372
-10,088
-31% -$48.3K
KALV
443
DELISTED
KalVista Pharmaceuticals
KALV
$81K ﹤0.01%
10,984
-332
-3% -$2.44K
ARGS
444
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$73K ﹤0.01%
10,000
– –
GEVO icon
445
CALL
Gevo
GEVO
$372M
$67K ﹤0.01%
4,852
– –
SLS icon
446
CALL
SELLAS Life Sciences
SLS
$2.33B
$46K ﹤0.01%
53
– –
AFL icon
447
Aflac
AFL
$63.9B
– –
-198,734
Closed -$7.2M
ALLE icon
448
Allegion
ALLE
$14.3B
– –
-53,997
Closed -$4.09M
ALSN icon
449
Allison Transmission
ALSN
$9.8B
– –
-270,365
Closed -$9.75M
AMZN icon
450
Amazon
AMZN
$2.94T
– –
-1,695,740
Closed -$75.2M
16 17
18
19 20

Similar funds

Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM

Alyeska Investment Group's Q2 2017 Portfolio in Review

As of Q2 2017, Alyeska Investment Group held 637 positions worth $12B, down 2.9% from $12.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Alyeska Investment Group withdrew a net $617M in Q2 2017, closing 191 positions and reducing 150 holdings. Its most notable exit was Eli Lilly, an estimated $133M position sold in full.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Alyeska Investment Group opened a new position in AbbVie worth $128M.

  • Alyeska Investment Group's largest Q2 2017 buy was AbbVie: 1,771,895 shares worth $128M.
  • Alyeska Investment Group added most to Delta Air Lines in Q2 2017, an estimated $140M increase.
  • Alyeska Investment Group's biggest Q2 2017 reduction was Oracle, cutting an estimated $146M.
  • Alyeska Investment Group fully exited Eli Lilly in Q2 2017, selling an estimated $133M.
  • Alyeska Investment Group's ten largest holdings make up 12% of its $12B portfolio in Q2 2017.
  • Alyeska Investment Group opened 171 new positions and closed 191 in Q2 2017.
  • Alyeska Investment Group's portfolio value fell 2.9% quarter-over-quarter to $12B.

Based on Alyeska Investment Group's 13F filing for Q2 2017, filed 14 Aug 2017.